{"id":4515,"date":"2024-06-19T15:09:39","date_gmt":"2024-06-19T08:09:39","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=4515"},"modified":"2024-06-19T15:09:39","modified_gmt":"2024-06-19T08:09:39","slug":"tang-prize-in-biopharmaceutical-science-honoring-three-scientists","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=4515","title":{"rendered":"Tang Prize in Biopharmaceutical Science Honoring Three Scientists"},"content":{"rendered":"

TAIPEI<\/span><\/span>, June 19, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0In a continuing series of laureate announcements, the Tang Prize Foundation today (June 19th<\/span>)<\/span> announced the 2024 Tang Prize in Biopharmaceutical Science recipients. The prestigious award has been jointly awarded to Joel F. Habener<\/span>, Svetlana Mojsov, and Jens Juul Holst<\/span>, for the discovery of GLP-1 (7-37) as an insulinotropic factor and the development of GLP-1 (7-37)-based anti-diabetic and anti-obesity drugs.<\/p>\n

\n

<\/a>
Tang Prize in Biopharmaceutical Science Honoring Three Scientists<\/span><\/p>\n<\/div>\n

Of the 8 billion people in the world today, as many as 500 million have diabetes, and nearly 1 billion are obese. The two diseases lead to many severe complications, resulting in a heavy medical burden for both the individual and society. Fortunately, GLP-1-based therapeutics have recently become blockbuster drugs to treat obesity and diabetes. At present, there are at least 13 GLP-1 RA (GLP-1 receptor agonists) drugs approved by the FDA for treating diabetes and obesity, benefiting hundreds of millions of users with prospects of even greater benefits in the future.<\/p>\n

The journey of the exciting discovery began with cloning the\u00a0anglerfish preproglucagon gene in the early 80s by Dr. Joel Habener<\/span> from Mass General Hospital\/ Harvard Medical School<\/span>. He discovered this precursor protein contains glucagon and another glucagon-related peptide (GRP). Subsequent cloning of the rat preproglucagon gene showed that it contained glucagon and two additional peptides designated GLP-1 and GLP-2, and that the anglerfish GRP is a GLP-1. Dr. Svetlana Mojsov, working at the Endocrine Unit and head of the HHMI peptide synthesis facility at Mass General Hospital, later identified the active form of intestinal GLP-1 to be GLP-1 (7-37). She collaborated with Dr. Habener to show that GLP-1 (7-37) can induce insulin release from the pancreas rather than the entire GLP-1 (1-37). This is an important discovery that identified the long-sought-after incretin and led to its application as an anti-diabetic strategy. The efforts of Dr. Mojsov in the synthesis of GLP-1 (7-37) and the development of several experimental approaches to detect the GLPs in the intestines were critical. Dr. Habener, Dr. Mojsov, and their collaborators showed in healthy and type 2 diabetic human subjects that GLP-1 (7-37) is insulinotropic, paving the way for clinical application.\u00a0 Independently at the University of Copenhagen<\/span>, Denmark, Dr. Jens Juul Holst<\/span> also isolated and identified GLP-1 (1-37), and subsequently GLP-1 (7-36) amide as an active incretin. His lab characterized the biology and physiology of GLP-1 (7-37), demonstrated its therapeutic potential, and has been actively involved in developing anti-diabetic drugs. Dr. Holst also reported that GLP-1 (7-37) inhibits gastric acid release and slows down gastric emptying, with anti-obesity potential. During clinical trials, it was found that diabetic patients receiving this type of drug had weight loss tendencies, further promoting its application in the treatment of obesity.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TAIPEI<\/span><\/span>, June 19, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0In a continuing series of laureate announcements, the Tang Prize Foundation today (June 19th<\/span>)<\/span> announced the 2024 Tang Prize in Biopharmaceutical Science recipients. The prestigious award has been jointly awarded to Joel F. Habener<\/span>, Svetlana Mojsov, and Jens Juul Holst<\/span>, for the discovery of GLP-1 (7-37) as an insulinotropic factor and the development of GLP-1 (7-37)-based anti-diabetic and anti-obesity drugs.<\/p>\n

\n

<\/a>
Tang Prize in Biopharmaceutical Science Honoring Three Scientists<\/span><\/p>\n<\/div>\n

Of the 8 billion people in the world today, as many as 500 million have diabetes, and nearly 1 billion are obese. The two diseases lead to many severe complications, resulting in a heavy medical burden for both the individual and society. Fortunately, GLP-1-based therapeutics have recently become blockbuster drugs to treat obesity and diabetes. At present, there are at least 13 GLP-1 RA (GLP-1 receptor agonists) drugs approved by the FDA for treating diabetes and obesity, benefiting hundreds of millions of users with prospects of even greater benefits in the future.<\/p>\n

The journey of the exciting discovery began with cloning the\u00a0anglerfish preproglucagon gene in the early 80s by Dr. Joel Habener<\/span> from Mass General Hospital\/ Harvard Medical School<\/span>. He discovered this precursor protein contains glucagon and another glucagon-related peptide (GRP). Subsequent cloning of the rat preproglucagon gene showed that it contained glucagon and two additional peptides designated GLP-1 and GLP-2, and that the anglerfish GRP is a GLP-1. Dr. Svetlana Mojsov, working at the Endocrine Unit and head of the HHMI peptide synthesis facility at Mass General Hospital, later identified the active form of intestinal GLP-1 to be GLP-1 (7-37). She collaborated with Dr. Habener to show that GLP-1 (7-37) can induce insulin release from the pancreas rather than the entire GLP-1 (1-37). This is an important discovery that identified the long-sought-after incretin and led to its application as an anti-diabetic strategy. The efforts of Dr. Mojsov in the synthesis of GLP-1 (7-37) and the development of several experimental approaches to detect the GLPs in the intestines were critical. Dr. Habener, Dr. Mojsov, and their collaborators showed in healthy and type 2 diabetic human subjects that GLP-1 (7-37) is insulinotropic, paving the way for clinical application.\u00a0 Independently at the University of Copenhagen<\/span>, Denmark, Dr. Jens Juul Holst<\/span> also isolated and identified GLP-1 (1-37), and subsequently GLP-1 (7-36) amide as an active incretin. His lab characterized the biology and physiology of GLP-1 (7-37), demonstrated its therapeutic potential, and has been actively involved in developing anti-diabetic drugs. Dr. Holst also reported that GLP-1 (7-37) inhibits gastric acid release and slows down gastric emptying, with anti-obesity potential. During clinical trials, it was found that diabetic patients receiving this type of drug had weight loss tendencies, further promoting its application in the treatment of obesity.<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-4515","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/4515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4515"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/4515\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}